CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma

Ting Li¹, Yingying Cheng¹, Pingzhang Wang¹, Wenyuan Wang¹, Fengzhan Hu², Xiaoning Mo¹, Hongxia Lv¹, Tao Xu²* and Wenling Han¹*

Abstract

Background: Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene family involved in multiple malignancies. CMTM4 is a member of this family and is located at chromosome 16q22.1, a locus that harbours a number of tumour suppressor genes. It has been defined as a regulator of cell cycle and division in HeLa cells; however, its roles in tumourigenesis remain poorly studied.

Methods: An integrated bioinformatics analysis based on the array data from the GEO database was conducted to view the differential expression of CMTM4 across multiple cancers and their corresponding control tissues. Primary clear cell renal cell carcinoma (ccRCC) and the paired adjacent non-tumour tissues were then collected to examine the expression of CMTM4 by western blotting, immunohistochemistry, and quantitative RT-PCR. The ccRCC cell lines A498 and 786-O and the normal renal tubular epithelial cell line HK-2 were also tested for CMTM4 expression by western blotting. Cell Counting Kit-8 (CCK-8) and viable cell counting assays were used to delineate the growth curves of 786-O cells after CMTM4 overexpression or knockdown. Wound healing and transwell assays were performed to assess the cells’ ability to migrate. The effects of CMTM4 on cellular apoptosis and cell cycle progression were analysed by flow cytometry, and cell cycle hallmarks were detected by western blotting and RT-PCR. The xenograft model in nude mice was used to elucidate the function of CMTM4 in tumourigenesis ex vivo.

Results: By omic data analysis, we found a substantial downregulation of CMTM4 in ccRCC. Western blotting then confirmed that CMTM4 was dramatically reduced in 86.9 % (53/61) of ccRCC tissues compared with the paired adjacent non-tumour tissues, as well as in the 786-O and A498 ccRCC cell lines. Restoration of CMTM4 significantly suppressed 786-O cell growth by inducing G2/M cell cycle arrest and p21 upregulation, and cell migration was also inhibited. However, knockdown of CMTM4 led to a completely opposite effect on these cell behaviours. Overexpression of CMTM4 also markedly inhibited the tumour xenograft growth in nude mice.

Conclusions: CMTM4 is downregulated and exhibits tumour-suppressor activities in ccRCC, and could be exploited as a target for ccRCC treatment.

Keywords: CMTM4, Clear cell renal cell carcinoma, Brain cancer, Tumour suppressor gene, G2/M cell cycle arrest, p21

* Correspondence: xutao@medmail.com.cn; hanwl@bjmu.edu.cn

1Department of Urology, Peking University People’s Hospital, 11 Xi-Zhi-Men South Street, Beijing 100044, China
2Department of Urology, Peking University People’s Hospital, 11 Xi-Zhi-Men South Street, Beijing 100044, China
3Peking University Center for Human Disease Genomics, Department of Immunology, Key Laboratory of Medical Immunology, Ministry of Health, School of Basic Medical Sciences, Peking University Center for Human Disease Genomics, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China

© 2015 Li et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Renal cell carcinoma (RCC) is the most prevalent malignancy of the kidney, and it accounts for 2.4 % of all adult malignancies [1]. Clear cell renal cell carcinoma (ccRCC) represents the predominant histologic subtype of RCC and constitutes approximately 80-90 % of all cases [1, 2]. Surgery is the most effective treatment of early and local ccRCCs, but after the resection for local disease, 20–40 % patients will develop recurrence [3], mainly due to the tumour’s high resistance to both chemotherapy and radiotherapy [2, 4]. Therefore, it is of paramount importance to understand the molecular mechanisms underlying the tumourigenesis of ccRCC. The identification of novel genes that are functionally involved in the initiation and progression of ccRCC may provide more sophisticated early diagnostic and further therapeutic strategies.

The human chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene family consisting of nine members, CKLF and CMTM1-8 [5, 6]. Their encoded products are structurally and functionally intermediate between classical chemokines and the transmembrane-4 superfamily (TM4SF), playing important roles in the immune system [7–11], the male reproductive system [12–14] and tumourigenesis [15–25]. Several members, such as CMTM3, 5, 7 and 8, have been reported to exhibit tumour suppressor functions in many types of malignancies, including gastric, pancreatic, liver, lung, cervical, oral, ovarian and oesophageal cancers [15–25].

CMTM4 is the most conserved member of this family and forms a gene cluster with CKLF and CMTM1-3 on chromosome 16q22.1, a locus that is frequently deleted or modified in multiple tumours and that harbours a number of tumour suppressor genes [26–33]. CMTM4 encodes three transcript variants, CMTM4-v1, -v2 and -v3. Among them, CMTM4-v2 is the full length cDNA product and is highly conserved in most vertebrate animals [34]. In HeLa cells, knockdown of CMTM4 can lead to cell cleavage defects and binucleated cells after mitosis [35], while overexpression of CMTM4-v1 and -v2 can inhibit cell growth by causing G2/M phase arrest without inducing apoptosis [34]. These findings suggest that CMTM4 might be an important gene involved in cell growth and cell cycle regulation. However, the function of CMTM4 in tumourigenesis remains poorly defined. In this study, we analysed the expression pattern of CMTM4 using a bioinformatics strategy and focused on its expression and function in ccRCC.

Materials and methods

Bioinformatics

All of the array data related to cancers from the Affymetrix human genome U133 plus 2.0 platform were downloaded from the GEO database (http://www.ncbi.nlm.nih.gov/geo/), and a TumourProfile database (http://tumour.bjmu.edu.cn/, unpublished) has been developed to analyse the differentially expressed genes in tumours using previously described data processing and microarray analysis methods [36, 37]. The expression profile of CMTM4 in a variety of cancers and the corresponding control (normal or non-tumour) tissues was searched in this database, and the expression levels were represented as average rank scores (ARS). Rank-based gene expression (RBE) curves, which visually reflected the gene expression profile (GEP) across multiple tissues, were generated using the TumourProfile data set.

Patient samples

A total of 61 patients with ccRCC (aged 22 to 78 years, median age of 60 years) who underwent surgery between January 2013 and April 2014 at the Department of Urology, Peking University People’s Hospital (Beijing, China) were enrolled in the present study. Paired tumour and adjacent non-tumour tissues were collected and tested for CMTM4 expression. All of the specimens were pathologically confirmed. The paraffin-embedded blocks of tumour tissues from each patient were assembled from the archival collections at the Department of Pathology. All participants gave informed consent according to the Helsinki Declaration, and the protocol for the present study was approved by the Ethics Committee of Peking University People’s Hospital (Beijing, China).

Cell lines, adenovirus and siRNAs

The ccRCC cell lines A498 and 786-O and the normal renal tubular epithelial cell line HK-2 were routinely cultured in MEM (Invitrogen, Carlsbad, CA, USA), RPMI-1640 (HyClone, Logan, UT), and K-SFM medium ( Gibco™ Life Technologies, Grand Island, NY) containing 10 % FBS (HyClone) supplemented with 1 % penicillin/streptomycin, respectively. All cells were grown at 37 °C in a humidified incubator containing 5 % CO2. Adenoviruses carrying the CMTM4 gene (Ad-CMTM4) and the empty adenovirus (Ad-null) were packaged by AGTC Gene Technology Company Ltd. (Beijing, China). The 786-O cells were infected with the adenoviruses at an MOI of 100. Small interfering RNAs (siRNAs) targeting CMTM4 were designed and chemically synthesised by GenePharma Co., Ltd. (Suzhou, China). The following sequences were used: si-CMTM4-3, 5′-GAAAUUGCUGCGCGAUAUTT-3′ (sense), 5′-AUAUCACGGCAGCAUUUACTT-3′ (antisense); si-CMTM4-6, 5′-GCAUAUGCAGUACACACAU3′ (sense), 5′-AUGUGUUCACUGCAUGCTT-3′ (antisense); and negative control (si-NC), 5′-UUCUCGACGUGUGUCACGT-3′ (sense), 5′-ACGUGACACGUGCGGAGATT-3′ (antisense). 786-O cells were transfected with the siRNAs using Lipofectamine™ 3000 (Life Technologies,
Grand Island, NY) according to the manufacturer’s instructions.

Protein extraction and western blotting
The cells were lysed in RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) supplemented with a 1 % protease inhibitor cocktail (Roche, Basel, Switzerland). The protein concentrations were determined using BCA protein assays (Pierce, Rockford, IL, USA). The whole cell lysates were then fractionated using 12.5 % or 15 % SDS–PAGE gels and electrotransferred onto polyvinylidene difluoride membranes (Hybond; GE Healthcare, Buckinghamshire, United Kingdom). Western blotting was performed as previously described [18]. The rabbit anti-CMTM4 pAb was prepared in our lab [38]. The anti-cyclin B1, –cyclin E, –cyclin-D1, –p21 and -p27 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). β-actin blotting was used as a lysate loading control. The density of the bands was analysed by ImageJ software (National Institutes of Health, Bethesda, Maryland, U.S.). The absolute intensity of the target protein was normalised to the absolute intensity of β-actin.

PCR and qPCR
The total RNAs were isolated from ccRCC tissues and cell lines using TRIzol reagent (Invitrogen). Reverse transcription was performed according to standard protocols using a RevertAid™ II First Strand cDNA synthesis Kit (Thermo Fisher Scientific Inc., Waltham, MA USA). Semi-quantitative and quantitative PCR (qPCR) were performed as previously described [18]. GAPDH was amplified as an internal standard. The primers for PCR of CMTM4 were as follows: CMTM4V2-F: 5′-CAGAAATGCTGGCGTG AT-3′, CMTM4V2-R: 5′-TGACTGAGAGCCACC G-3′, and the 72# probe (Roche) was used for qRT-PCR of CMTM4. The primers for PCR of p21 were p21-F: 5′-C TCAGAGGAGGCCTGTC-3′ and P21-R: 5′-TTAG GGCTTCTCTTGAGGAAG-3′.

Immunohistochemistry (IHC)
Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded clinical tissues as previously described [18]. A rabbit anti-CMTM4 pAb (4 mg/L) was used as the primary antibody.

Cell proliferation assay
Cell proliferation was analysed using the Cell Counting Kit-8 (CCK-8, Dojindo Laboratories, Kumamoto, Japan) and viable cell counting assays. For the CCK-8 assays, the cells were seeded in 96-well plates at a density of 3000 cells per well and then incubated at 37 °C in a 5 % CO2 humidified atmosphere. At the indicated time points, 10 μL CCK-8 solution was added into each well and incubated for 2 h. The absorbance at 450 nm was measured to assess the number of viable cells. The results were obtained from three independent experiments in triplicate. For the viable cell counting assays, the cells were seeded in 24-well plates at a density of 20,000 cells per well. The viable cells marked by trypan blue exclusion were counted using a Vi-CELL TM_XR Cell Viability Analyzer (Beckman Coulter, Inc., Brea, CA, USA).

Flow cytometry
Cellular apoptosis was evaluated by FITC-conjugated Annexin V/prodium iodide (PI) staining followed by flow cytometry analysis, as previously described [18]. For the cell cycle analysis, the cells were harvested 48 h after infection with adenoviruses or transfection with siRNAs. After washing with PBS, the cells were fixed in ice-cold 70 % ethanol overnight at −20 °C. The fixed cells were then pelleted by centrifugation, washed twice in PBS, and incubated in PBS containing 500 mg/mL RNase A (Sigma-Aldrich) at 37 °C for 30 min. After staining with 10 mg/mL PI (Sigma-Aldrich) in 0.1 % Triton X-100, the cells were collected on a BD FACSCalibur (BD Bioscience, San Jose, CA, USA). The cell cycle distribution was analysed with the ModFit LT software (Verity Software House, Topsham, ME).

Wound healing assay
The 786-O cells infected with Ad-CMTM4 or Ad-null were cultured in 24-well plates until confluent. The cell layer was then scratched using a sterile 10 μL micropipette tip and washed twice with and subsequently maintained in serum-free media. The cells were photographed 0, 24 and 48 h after wounding.

Cell migration assay
Forty-eight hours after infection or transfection, the 786-O cells were serum-starved for 6 h. Then, 3 × 10^4 cells in 250 μL serum-free media were seeded into the upper chamber of a transwell with a fibronectin-coated filter (8-mm pore size, Corning Life Sciences, NY, USA). The bottom chamber contained medium supplemented with 10 % FBS. After a 14-h (for the siRNA-transfected cells) or 16-h (for the adenovirus-infected cells) incubation at 37 °C in a 5 % CO2 humidified atmosphere, the nonmigrated cells were scraped off of the filter using a cotton swab and the migrated cells were stained with crystal violet following fixation with 4 % paraformaldehyde. The number of cells was counted in 8 randomly chosen fields (magnification, ×200). Triplicate wells were performed in each assay, and the assay was repeated at least three times.

Xenograft model in nude mice
All protocols for the animal studies were reviewed and approved by the institutional Animal Research Ethics
Board. Female BALB/c nude mice (4–6 weeks old, weighing 18–22 g) were maintained in a germ-free environment in the animal facility. The tumourigenesis assay was performed as previously described, with some modifications [39]. Briefly, $5 \times 10^6$ Ad-CMTM4- or Ad-null-infected 786-O cells in 100 μL PBS were injected

| Tissue                        | Sample size | ARS   | $P$-value $^a$  | Bonferroni $^b$ |
|-------------------------------|-------------|-------|-----------------|-----------------|
| bladder cancer                | 186         | 76.85 | 0.0068754       | 1               |
| bladder control               | 64          | 68.66 |                 |                 |
| astrocytoma                   | 207         | 89.69 | 1.68E-12        | 9.18E-08        |
| ependymoma                    | 152         | 94.47 | 0.0024976       | 1               |
| glioblastoma $^d$             | 498         | 86.55 | 3.01E-28        | 1.65E-23        |
| medulloblastoma $^d$          | 302         | 77.27 | 8.22E-49        | 4.48E-44        |
| meningioma $^d$               | 89          | 85.75 | 1.69E-24        | 9.24E-20        |
| neuroblastoma $^d$            | 221         | 75.38 | 5.83E-47        | 3.18E-42        |
| oligodendroglioma             | 117         | 87.55 | 7.10E-07        | 0.038745        |
| retinoblastoma $^d$           | 78          | 71.50 | 7.52E-29        | 4.11E-24        |
| brain control                 | 104         | 94.09 |                 |                 |
| breast cancer                 | 3080        | 86.27 | 0.0209644       | 1               |
| breast control                | 374         | 85.54 |                 |                 |
| colorectal adenocarcinoma      | 1841        | 92.80 | 3.59E-91        | 1.96E-86        |
| colon mucosa normal           | 273         | 96.33 |                 |                 |
| gastric cancer                | 681         | 87.53 | 9.01E-13        | 4.91E-08        |
| gastric control               | 61          | 92.61 |                 |                 |
| head and neck squamous cell carcinoma | 220 | 80.40 | 0.0990636 | 1 |
| head and neck squamous cell control | 59  | 83.71 |                 |                 |
| ccRCC $^d$                     | 652         | 83.83 | 1.58E-100       | 8.60E-96        |
| kidney control                | 244         | 95.42 |                 |                 |
| hepatocellular carcinoma      | 263         | 68.85 | 0.4185167       | 1               |
| liver control                 | 62          | 69.47 |                 |                 |
| lung adenocarcinoma           | 1158        | 86.85 | 2.46E-06        | 0.1344489       |
| lung squamous cell carcinoma  | 422         | 82.11 | 1.11E-15        | 6.09E-11        |
| lung control                  | 333         | 85.84 |                 |                 |
| oral squamous cell carcinoma  | 339         | 80.12 | 0.0026408       | 1               |
| oral squamous cell control    | 118         | 81.62 |                 |                 |
| ovarian cancer                | 379         | 86.87 | 2.78E-05        | 1               |
| ovary control                 | 120         | 89.28 |                 |                 |
| pancreatic cancer             | 263         | 84.44 | 0.0205749       | 1               |
| pancreas control              | 83          | 86.73 |                 |                 |
| prostate cancer               | 345         | 86.29 | 6.11E-12        | 3.33E-07        |
| prostate control              | 81          | 72.88 |                 |                 |
| skin melanoma                 | 522         | 79.30 | 6.76E-15        | 3.69E-10        |
| skin normal                   | 305         | 84.12 |                 |                 |

$^a$ARS denotes the average rank score

$^b$The $P$-values were calculated using the Wilcoxon rank-sum test in the R (http://www.r-project.org/) software environment and are relative to the corresponding normal or non-tumour tissues

$^c$The $P$-values were adjusted using Bonferroni correction in the function "p.adjust" in the R software

$^d$The expression levels of CMTM4 in the underlined tissues were considered to be significantly downregulated by fully considering the differences in the ARS values, the Bonferroni correction adjusted $P$-values and the RBE curves shown in Fig. 1
subcutaneously into the right and left flanks of nude mice, respectively. The tumour diameter was measured with a calliper every 3 days, and the tumour volume was calculated by length \( \times \) width\(^2 \times 0.5 \). The mice were sacrificed at day 27, when the tumours were dissected, weighed and lysed for western blotting analysis.

**Statistical analysis**

The bioinformatics analysis of the differences in CMTM4 expression between the cancers and control tissues were evaluated using the Wilcoxon rank-sum test in the R (http://www.r-project.org/) software environment. Bonferroni’s correction of the R function “p.adjust” was used to adjust the \( p \)-values. The experimental data were analysed using SPSS software 17.0 (SPSS, Inc., Chicago, IL, USA). CMTM4 expression was correlated with the clinical characteristics using one-way ANOVA (for the classification variables, such as gender, stage and grade) or Pearson’s correlation analysis for two variables (for the continuous variables, such as age). The differences between two independent groups were analysed using Student’s t test. A \( p \)-value < 0.05 was considered to represent a statistically significant difference.

**Results**

CMTM4 is downregulated in ccRCC and brain cancers according to the omic data analysis

Gene expression profiles can reveal essential clues regarding a gene’s function. To assess the potential of CMTM4 as a tumour suppressor, we performed an integrated bioinformatics analysis based on the omic tumour data set from the GEO database to determine the differential expression of CMTM4 across multiple cancers and their corresponding control (normal or non-tumour) tissues at the mRNA level. The average rank scores (ARS), Bonferroni correction adjusted \( p \)-values (Table 1), and rank-based gene expression (RBE) curves (Fig. 1) were synthesised, and CMTM4 was most significantly downregulated in ccRCC and several brain cancers, such as neuroblastoma, glioblastoma, and medulloblastoma, while no apparent differences were observed in breast cancers, lung adenocarcinomas, hepatocellular carcinomas (HCCs), etc. The downregulation of CMTM4 in glioblastoma has been verified by a recent study [25], and that in ccRCC is further supported by the BioXpress (http://hive.biochemistry.gwu.edu/tools/bioxpress) [40] and the protein atlas (http://www.proteinatlas.org/ENSG00000183723-CMTM4/cancer) databases. The BioXpress database indicates that CMTM4 is downregulated in 95.83 % of ccRCC samples.
compared with their paired normal samples based on RNA sequencing (RNA-seq); the data set deposited in the Cancer Genome Atlas (TCGA) from a total of 128 patients has been collected and used for the analysis [40]. The protein atlas indicates that the CMTM4 protein is also expressed at lower levels in renal cancer tissues \((n = 12, \text{ in general, weakly stained or negative})\) than in normal kidney tissues \((n = 2, \text{ moderately positive})\).

CMTM4 is frequently reduced in ccRCC tissues and cell lines

According to the bioinformatics analysis, we then examined CMTM4 expression in 61 paired ccRCC tissues and adjacent normal tissues by western blotting. Compared to the non-tumour tissue, CMTM4 was dramatically downregulated in the ccRCC tissue. As the bands detected in western blotting were identical to those for the overexpressed CMTM4-v2 \((\sim24 \text{ kDa, Fig. 3a})\), we focused on CMTM4-v2 in the subsequent studies, and the term “CMTM4” was used to indicate “CMTM4-v2”. The western blotting results of three representative paired tissues are shown in Fig. 2a, and quantitative analysis of the western blotting results of all 61 paired tissues was performed by normalizing the band density of CMTM4 to \(\beta\)-actin. The relative CMTM4 expression level was calculated for the tumour versus paired adjacent non-tumour tissue. As shown in Fig. 2b, the expression of CMTM4 was frequently downregulated in ccRCC tissues \((53/61, 86.9\%)\) compared to the matched adjacent non-tumour tissues. We further analysed CMTM4 expression in representative samples by immunohistochemistry and qRT-PCR and obtained consistent results (Fig. 2c and d). Likewise, CMTM4 expression was also significantly lower in the ccRCC cell lines \((786-O \text{ and } A498)\) than in the normal renal tubular epithelial line HK-2 by western blotting (Fig. 2e).

Correlations between CMTM4 expression and the clinical features

We also analysed the association between multiple clinical features of ccRCC patients and the expression of
CMTM4 and observed no correlation between the CMTM4 expression levels and the parameters, including age, gender, clinical stage, and histologic grade (Table 2).

**CMTM4 inhibits 786-O cell growth**

The reduced expression of CMTM4 in ccRCC prompted us to determine whether it plays an inhibitory role in tumourigenesis. The 786-O cells, in which CMTM4 was expressed at low levels, were infected with a CMTM4-expressing or empty adenovirus (Ad-CMTM4 or Ad-null), and cell growth was monitored over a 96-h period. The overexpression of CMTM4 was detected by western blotting (Fig. 3a). The CCK-8 (Fig. 3b) and viable cell counting (Fig. 3c) assays showed that CMTM4 significantly inhibited the proliferation of 786-O cells compared with the Ad-null infectants. Consistently with this finding, knockdown of CMTM4 with two siRNAs (si-CMTM4-3 and 6) in 786-O cells (Fig. 3d) was more potent than the negative control (si-NC) in promoting cell growth (Fig. 3e and f).

**CMTM4 causes G2/M cell cycle arrest**

To elucidate the mechanisms underlying the tumour cell growth inhibition by CMTM4, its effects on apoptosis and cell cycle progression were studied by flow cytometry. FITC-Annexin V/PI staining indicated that overexpression of CMTM4 did not induce apoptosis of 786-O cells 72 h after infection (Fig. 4a). However, the Ad-CMTM4-infected cells had a significant increase in the G2/M phase population compared with the Ad-null infectants (Fig. 4b). We further examined several key cell cycle regulators by western blotting and found that p21 expression was upregulated in the CMTM4-expressing 786-O cells compared with the controls, whereas p27 and Cyclin B1, E and D1 were unaffected (Fig. 4c). RT-PCR was then performed and demonstrated that p21 expression was also upregulated at the mRNA level (Fig. 4d). However, knockdown of CMTM4 reduced the G2/M phase accumulation (Fig. 4e) and p21 expression at both the protein and mRNA levels (Fig. 4f). These results suggested that CMTM4 induces cell cycle arrest at the G2/M phase by upregulating p21 in 786-O cells.

**CMTM4 inhibits 786-O cell migration**

Migration is another important aspect of tumourigenesis and has been reported to be negatively regulated by p21 [41]. We then explored the impact of CMTM4 on ccRCC cell migration. Wound-healing assays were first performed, and wound closure was found to be retarded for CMTM4-overexpressing 786-O cells (Fig. 5a). Transwell assays were then conducted to evaluate the motility of CMTM4 overexpressing or knockdown 786-O cells. Compared with their respective controls, overexpression of CMTM4 led to a significant decrease in the number of migrated cells (Fig. 5b), while knockdown of CMTM4 increased the number of 786-O cells that crossed over the filter (Fig. 5c).

**CMTM4 suppresses tumour growth ex vivo**

The in vitro experiments demonstrated that CMTM4 exhibited antitumourigenic activities in ccRCC; therefore, we subsequently used a xenograft model in nude mice to confirm the ex vivo tumour-suppressor activity of CMTM4. 786-O cells infected with Ad-CMTM4 or Ad-null were injected subcutaneously into the right and

### Table 2 Correlations between CMTM4 expression and the clinical features of the ccRCC patients

| Clinical factors | Sample size | Mean ratio, T/N ± SEM a | Correlation coefficient | P –value b |
|------------------|-------------|------------------------|------------------------|------------|
| Gender c         |             |                        |                        |            |
| Male             | 39          | 0.290 ± 0.318          |                        | 0.863      |
| Female           | 22          | 0.223 ± 0.233          |                        |            |
| Age              | 61          | 0.182 ± 0.039          |                        | 0.127      |
| Stage c          |             |                        |                        |            |
| I                | 50          |                        |                        | n.a. c     |
| II               | 3           |                        |                        |            |
| III              | 5           |                        |                        |            |
| IV               | 3           |                        |                        |            |
| Grade            |             |                        |                        |            |
| 1                | 27          | 0.282 ± 0.050          |                        | n.a. c     |
| 2                | 26          | 0.567 ± 0.313          |                        |            |
| 3                | 2           |                        |                        |            |

a The relative CMTM4 expression level was calculated from the tumour (T) versus paired adjacent non-tumour tissue (N).
b The P-value was calculated using one-way ANOVA (for the classification variables, such as gender, stage and grade) or Pearson correlation analysis for two variables (for the continuous variables, such as age).
c n.a. indicates not available due to a small sample size.
d The tumour stage was defined according to TNM (International Union Against Cancer, 6th edition, 2002).
left flanks of nude mice, respectively. The tumours appeared approximately one week after implantation. Within 4 weeks, the volume and weight of tumours from the CMTM4 overexpressing cells were significantly smaller than those of the controls (Fig. 6a-c). We also detected the expression of p21 in the tumour xenografts by western blotting and found that it was decreased in the CMTM4 overexpressing tumours (Fig. 6d). These data confirmed that CMTM4 exhibits tumour suppressor activities in ccRCC.

Discussion

The tumour suppressor functions of members of the CMTM family, particularly CMTM3, 5, 7 and 8, have been extensively studied in multiple types of malignancies. In contrast, CMTM4 remains less investigated. A comprehensive analysis of CMTM4 expression across multiple cancers using bioinformatics indicated that CMTM4 is most significantly downregulated in brain cancers and ccRCC, which implies a tissue-specific function of CMTM4. Currently, omic data analysis has become a major trend in numerous fields, among which gene expression profile (GEP) analysis is generally an essential step in functional gene studies. Analyses using other databases, as well as Delic S. and colleagues’ [25] and our experimental data, demonstrate the viability of our analysis method [37] in GEP predictions, with high efficiency and accuracy.

Using a total of 61 paired ccRCC tissues and adjacent normal tissues, we show that CMTM4 expression is frequently downregulated in renal cancer tissues. However, the expression levels of CMTM4 were not correlated with the patients’ gender and age. Because surgical resection is restricted to early and local ccRCCs, most patients are at stage one and histologically exhibit high and moderate differentiation (grade Ia and II). Therefore, this correlation was not available due to the limitation of the clinical samples. Moreover, the survival data are still being collected, because most of the patients had undergone surgical resection only a short time ago.

CMTM4 is tightly linked with CMTM1-3 on chromosome 16q22.1, a genomic region prone to both genetic and epigenetic modifications in various cancers. Chromosomal aberrations, such as deletions, amplifications [26–29], single nucleotide polymorphisms (SNPs) [30], loss of heterozygosity (LOH) and microsatellite instability (MSI) [31, 32], as well as aberrant methylations [29],
occur frequently in this region in different types of malignancies. Our previous studies have also shown that CMTM3 is frequently inactivated by promoter CpG methylation [18]. It remains to be clarified whether these mechanisms are also involved in the downregulation of CMTM4 in ccRCC.

Regular cell cycle progression is a key factor in cell proliferation, and alterations of the cell cycle may influence...
cell growth. CMTM4 has been suggested to be an important regulator of cell cycle progression and division in HeLa cells [34, 35]. Here, we also observed that overexpression of CMTM4 inhibited 786-O cell growth by inducing G2/M phase accumulation. p21 was increased in the process, which plays complex roles in tumourigenesis by regulating the cell cycle, senescence, apoptosis and migration [41]. Through its interaction with the Cdk1/CyclinB complex, the p21 protein interferes with the transition of cells from the G2 phase of the cell cycle into mitosis; moreover, by inhibiting the Rho cascade, p21 can also influence cytoskeletal factors and cell motility [41]. Therefore, the upregulation of p21 may be responsible for the tumour suppressor functions of CMTM4 in 786-O cells. However, increased p21 expression is not necessarily linked to growth arrest; thus, the sophisticated mechanism underlying the inhibitory activities of CMTM4 is still to be explored. On the other hand, p21 is well known to be induced by p53. In addition, several p53-independent pathways have also been identified.

**Fig. 5** CMTM4 inhibits 786-O cell migration. a Representative images (magnification, ×100) of adenovirus-infected 786-O cell migration in the wound-healing assay were photographed at 0, 24 and 48 h after scratching (left). The relative migration rate was calculated by dividing the change in the distance between the scratch edges by the initial distance (right). Transwell assays (magnification, ×100) were performed to evaluate the migration of adenovirus-infected (b) and siRNAs-transfected (c) 786-O cells. The statistical graph indicates the means ± SEM of the number of cells from 8 random high power fields (magnification, ×200) counted from three independent experiments.
Overexpression of CMTM4 increased p21 not only at the protein level but also at the mRNA level, whereas knockdown of CMTM4 decreased both. However, because p53 is inactive in 786-O cells [43], the mechanism by which CMTM4 regulates p21 and whether it influences the transcription or the degradation of the p21 mRNA requires further investigation.

**Conclusions**

In summary, CMTM4 is frequently reduced in ccRCC tissues and cell lines, according to omic data analysis as well as our experimental data. Restoration of CMTM4 suppresses the tumourigenicity of 786-O cells both in vitro and ex vivo, whereas knockdown of CMTM4 led to promoting effects. These observations highlight the
potential of CMTM4 as a tumour suppressor in ccRCC. A better understanding of the roles of CMTM4 in tumourigenesis may allow researchers to develop novel diagnostics and more effective treatment strategies for this malignancy.

Abbreviations
CMTM: Chemokine-like factor (CRLF)-like MARVEL transmembrane domain-containing family; GEO: Gene Expression Omnibus; RCC: Renal cell carcinoma; ccRCC: Clear cell renal cell carcinoma; ARS: Average rank score; RBE: Rank-based gene expression; GEP: Gene expression profile; MOX: Multiplicity of infection; siRNAs: Small interfering RNAs; qPCR: Quantitative PCR; IHC: Immunohistochemistry; CCK8: Cell Counting Kit-8; PI: Propidium iodide.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
WH and TX designed the project, supervised the study and revised the manuscript. TL performed the western blotting, RT-PCR, IHC, cell growth and migration assays, flow cytometry, and animal experiments and drafted the manuscript. WC participated in the animal experiments and statistical analyses. FH contributed to sample handling, storage and collection of the clinical data. XM performed the quantitative PCR. HL assisted in the semiquantitative PCR and plasmid construction. All authors read and approved the final manuscript.

Acknowledgements
We thank Prof. Dalong Ma for providing general support. This work was supported by grants from the National Natural Science Foundation of China (81273207 and 81472626).

Received: 6 July 2015 Accepted: 5 October 2015

References
1. Busch J, Balla B, Jung M, Wotscheskyf Z, Trujillo-Arribas E, Schwabe P, et al. Pw-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J Exp Clin Cancer Res. 2015;34:61.
2. Zhuang J, Tu X, Cao K, Guo S, Mao X, Pan J, et al. The expression and role of tyrosine kinase ETB/ERK in renal cell carcinoma. J Exp Clin Cancer Res. 2014;33:22.
3. Leibovich BC, Lohse CM, Crispens PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183:1309–15.
4. Grimm MO, Wolff I, Zastrow S, Frohner M, Wirth M. Advances in renal cell carcinoma treatment. Ther Adv Urol. 2010;2:11–7.
5. Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y, et al. Molecular cloning and characterization of chemokine-like factor 1 (CRLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 2001;357:127–35.
6. Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CRLF5F1–B) by in silico cloning and experimental validation. Genomics. 2003;81:609–17.
7. Chowdhury MH, NagaI A, Terashima M, Sheikh A, Murakawa Y, Kobayashi S, et al. Chemokine-like factor expression in the idiopathic inflammatory myopathies. Acta Neurol Scand. 2008;118:106–14.
8. Tian L, Li W, Wang J, Zhang Y, Zheng Y, Qi H, et al. The CRLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma. Allergy. 2011;66:287–97.
9. Zheng Y, Guo C, Zhang Y, Qi H, Sun Q, Xu E, et al. Alleviation of murine allergic rhinitis by C19, a C-terminal peptide of chemokine-like factor 1 (CRLF1). Int Immunopharmacol. 2011;11:2286–93.
10. Tan Y, Wang Y, Li L, Xia J, Peng S, He Y. Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis. PLoS One. 2015;10:e0125073.
34. Plate M, Li T, Wang Y, Mo X, Zhang Y, Ma D, et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through inducing G2/M phase accumulation. Mol Cells. 2010;29:355–61.

35. Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature. 2004;432:1036–40.

36. Wang P, Qi H, Song S, Li S, Huang N, Han W, et al. ImmuCo: a database of gene co-expression in immune cells. Nucleic Acids Res. 2015;43:D1133–9.

37. Wang P, Yang Y, Han W, Ma D. ImmuSort, a database on gene plasticity and electronic sorting for immune cells. Sci Rep. 2015;5:10370.

38. Li T, Guo X, Wang Y, Plate M, Shao L, Song Q, et al. Preparation, purification and characterization of the polyclonal antibody against human CMTM4. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24:41–4.

39. Ji SQ, Yao L, Zhang XY, Li XS, Zhou LQ. Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer Res. 2012;31:22.

40. Wan Q, Dingerdissen H, Fan Y, Gulzar N, Pan Y, Wu TJ, et al. BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis. Database (Oxford). 2015; doi: 10.1093/database/bav019.

41. Cmielova J, Rezacova M. p21Cip1/Waf1 protein and its function based on a subcellular localization [corrected]. J Cell Biochem. 2011;112:3502–6.

42. Weinberg WC, Denning MF. P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med. 2002;13:453–64.

43. Ishimaru T, Lau I, Jackson AL, Modiano JF, Weiss RH. Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. J Urol. 2010;184:2143–9.